NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER
Biotech · Private
Altenex, a biologic drug consisting of exosomes derived from mesenchymal stem cells cultured on engineered 3D scaffolds for tendinopathy treatment
- Grants
- $6.0M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A product for osteoarthritis treatment and prevention | $243,994 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel product for tendinopathy treatment | $225,042 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel nutraceutical drug for tendinopathy treatment | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Gene and Stem Cell-Based Treatment for Tendinopathy | $225,392 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel product for tendinopathy treatment | $924,366 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel product for tendinopathy treatment | $20,300 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel product for tendinopathy treatment | $831,571 | |
| Federal grant | Department of Health and Human Services · Phase II · miRNA drug for tendinopathy | $737,376 | |
| Federal grant | Department of Health and Human Services · Phase II · miRNA drug for tendinopathy | $568,966 | |
| Federal grant | Department of Health and Human Services · Phase II · Exosome drug for tendinopathy | $766,269 | |
| Federal grant | Department of Health and Human Services · Phase II · miRNA drug for tendinopathy | $560,060 | |
| Federal grant | Department of Health and Human Services · Phase II · Exosome drug for tendinopathy | $719,580 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3094 | AGYPHARMA, LLC | — | — |
| 3095 | TINY CARGO COMPANY, THE | — | — |
| 3096 | NEUROLUX, INC. | — | — |
| 3097 | NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER | — | — |
| 3098 | ImmPORT Therapeutics Inc dba Antigen Discovery Inc | — | — |
| 3099 | ASSUAGE PHARMACEUTICALS, INC. | — | — |
| 3100 | TUNITAS THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.